Attenuation of adverse cardiac effects in prednisolone-treated δ-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism

Neuromuscular Disorders

Volumn 20, Issue 1, 2010, Pages 21-28

  Bauer, Ralf ^a,b   Blain, Alison ^a   Greally, Elizabeth ^a   Lochmüller, Hanns ^a   Bushby, Kate ^a   MacGowan, Guy A ^a,c   Straub, Volker ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Sarcoglycan; Cardiomyopathy muscular dystrophy; Glucocorticoids; Spironolactone

Indexed keywords

DELTA SARCOGLYCAN; PREDNISOLONE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL DAMAGE; CONTROLLED STUDY; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBER MEMBRANE; HEART MUSCLE FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLE;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; FIBROSIS; GLUCOCORTICOIDS; HEART; HEART DISEASES; HEMODYNAMICS; HORMONE ANTAGONISTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE CONTRACTION; ORGAN SIZE; PREDNISOLONE; RECEPTORS, MINERALOCORTICOID; SARCOGLYCANS; SARCOLEMMA; SPIRONOLACTONE;

EID: 74149083856     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2009.10.003     Document Type: Article

References (33)

1. Porter J.D., Khanna S., Kaminski H.J., et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11 (2002) 263-272
2. Bushby K., Muntoni F., Urtizberea A., Hughes R., and Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 14 (2004) 526-534
3. Silversides C.K., Webb G.D., Harris V.A., and Biggar D.W. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 91 (2003) 769-772
4. Markham L.W., Spicer R.L., Khoury P.R., Wong B.L., Mathews K.D., and Cripe L.H. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26 (2005) 768-771
5. Bauer R., MacGowan G.A., Blain A., Bushby K., and Straub V. Steroid treatment causes deterioration of myocardial function in the δ-sarcoglycan-deficient mouse model for dilated cardiomyopathy. Cardiovasc Res 79 (2008) 652-661
6. Heydemann A., and McNally E.M. Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. Trends Cardiovasc Med 17 (2007) 55-59
7. Ozawa E., Mizuno Y., Hagiwara Y., Sasaoka T., and Yoshida M. Molecular and cell biology of the sarcoglycan complex. Muscle Nerve 32 (2005) 563-576
8. Lapidos K.A., Kakkar R., and McNally E.M. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 94 (2004) 1023-1031
9. Danialou G., Comtois A.S., Dudley R., et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 15 (2001) 1655-1657
10. Wheeler M.T., and McNally E.M. Sarcoglycans in vascular smooth and striated muscle. Trends Cardiovasc Med 13 (2003) 238-243
11. Coral-Vazquez R., Cohn R.D., Moore S.A., et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98 (1999) 465-474
12. Hack A.A., Lam M.Y., Cordier L., et al. Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci 113 (2000) 2535-2544
13. Walker B.R. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157 (2007) 545-559
14. Qin W., Rudolph A.E., Bond B.R., et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93 (2003) 69-76
15. Nagata K., Obata K., Xu J., et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 (2006) 656-664
16. Rickard A.J., Funder J.W., Fuller P.J., and Young M.J. The role of the glucocorticoid receptor in mineralocorticoid/salt-mediated cardiac fibrosis. Endocrinology 147 (2006) 5901-5906
17. Funder J.W. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93 (2005) 121-125
18. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341 (1999) 709-717
19. Hayashi M., Tsutamoto T., Wada A., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107 (2003) 2559-2565
20. Katada J., Meguro T., Saito H., et al. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 111 (2005) 2157-2164
21. MacGowan G.A., Rager J., Shroff S.G., and Mathier M.A. In vivo alpha-adrenergic responses and troponin I phosphorylation: anesthesia interactions. J Appl Physiol 98 (2005) 1163-1170
22. Steendijk P., Staal E., Jukema J.W., and Baan J. Hypertonic saline method accurately determines parallel conductance for dual-field conductance catheter. Am J Physiol Heart Circ Physiol 281 (2001) H755-H763
23. Suga H., and Sagawa K. Instantaneous pressure-volume relationships and their ratio in the excised, supported canine left ventricle. Circ Res 35 (1974) 117-126
24. Glower D.D., Spratt J.A., Snow N.D., et al. Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable stroke work. Circulation 71 (1985) 994-1009
25. Hamer P.W., McGeachie J.M., Davies M.J., and Grounds M.D. Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat 200 (2002) 69-79
26. Pfaffl M.W., Horgan G.W., and Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30 (2002) e36
27. Connolly A.M., Schierbecker J., Renna R., and Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12 (2002) 917-925
28. Barbato J.C., Mulrow P.J., Shapiro J.I., and Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 40 (2002) 130-135
29. Doggrell S.A., and Brown L. The spironolactone renaissance. Expert Opin Investig Drugs 10 (2001) 943-954
30. Thai H.M., Do B.Q., Tran T.D., Gaballa M.A., and Goldman S. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 12 (2006) 240-245
31. Graham H.K., and Trafford A.W. Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure. Am J Physiol Heart Circ Physiol 292 (2007) H1364-H1372
32. Marijianowski M.M.H., Teelin P., Mann J., and Becker A.E. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ration: a quantitative assessment. J Am Coll Cardiol 25 (1995) 1263-1272
33. Kass D.A., Hare J.M., and Georgakopoulos D. Murine cardiac function: a cautionary tail. Circ Res 82 (1998) 407-415